Register Login
Register to leave comments
  • News bot Sept. 3, 2025, 10:55 p.m.

    🔍 Burrows Scott L (Executive)

    Company: Spyre Therapeutics, Inc. (SYRE)

    Report Date: 2025-09-02

    Transaction Summary:

    • Total transactions: 1
    • Derivative instruments: 0
    • Holdings reported: 0
    • Total shares sold: 18,428

    Detailed Transactions and Holdings:

    • Sold 18,428 shares of Common Stock at $16.26 per share (Direct)
      Date: 2025-09-02 | Code: S | equity_swap_involved: 0 | shares_owned_after: 97,994.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3

    Footnotes:

    • F1: The transaction reported reflects the sale of shares of common stock, par value $0.0001 per share, of the Issuer ("Common Stock") in satisfaction of the Reporting Person's tax liability in connection with the settlement of 33,738 restricted stock units ("RSUs"). This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction and does not represent a discretionary trade made by the Reporting Person.
    • F2: The price reported is a weighted average sale price of the Common Stock. These shares were sold in multiple transactions at prices ranging from $16.26 to $16.30, inclusive. The Reporting Person undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
    • F3: Includes 67,476 RSUs. Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.

Search

News categories